<DOC>
	<DOCNO>NCT00104260</DOCNO>
	<brief_summary>The primary objective evaluate degree frequency response Phenoptin™ ( sapropterin dihydrochloride ) , demonstrate reduction blood phenylalanine ( Phe ) level among subject phenylketonuria ( PKU ) elevate Phe level . A secondary objective study evaluate safety Phenoptin™ treatment subject population , identify individual subject population respond Phenoptin™ treatment reduction blood Phe level .</brief_summary>
	<brief_title>Study Evaluate Response Safety 8-Day Course Phenoptin™ Treatment Subjects With Phenylketonuria</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Age &gt; /= 8 year Blood Phe level &gt; /= 450 umol/L screen Clinical diagnosis PKU hyperphenylalaninemia document past medical history least one blood Phe measurement &gt; /= 360 umol/L ( 6 mg/dL ) Willing able provide write informed consent , case subject age 18 , provide write assent ( require ) write informed consent parent legal guardian , nature study explain Negative urine pregnancy test screening ( nonsterile female childbearing potential ) Male Female subject childbearing potential childbearing potential ( sexually active nonsterile ) must use acceptable birth control measure , determine investigator , willing continue use acceptable birth control measure participate study Willing able comply study procedure Willing continue current diet unchanged participate study Perceived unreliable unavailable study participation , age 18 , parent legal guardian perceive unreliable unavailable Use investigational agent within 30 day prior screen , requirement investigational agent vaccine prior completion schedule study assessment Pregnant breastfeeding , consider pregnancy ALT &gt; 5 time upper limit normal ( i.e. , Grade 3 high base World Health Organization Toxicity Criteria ) screen Concurrent disease condition would interfere study participation safety ( e.g. , seizure disorder , oral steroid–dependent asthma condition require oral parenteral corticosteroid administration , insulindependent diabetes , organ transplantation ) Serious neuropsychiatric illness ( e.g. , major depression ) currently medical control Requirement concomitant treatment drug know inhibit folate synthesis ( e.g. , methotrexate ) Concurrent use levodopa Clinical diagnosis primary BH4 deficiency</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>